Recombinant protein innovation supporting next-generation cell and gene therapy

The portfolio supports a wide range of applications, including CAR-T and TCR therapies, NK cell expansion, iPSC differentiation, and ex vivo gene editing workflows.

The launch represents Qkine’s commitment to empowering the cell therapy ecosystem with high-quality, regulatory-ready tools that streamline process development, accelerate timelines, and reduce risk in bringing life-changing therapies to patients.

The Cell Therapy Grade Proteins are available globally, with customization options for scale, formulation, and regulatory documentation packages.